Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.

ABSTRACT:

Introduction

Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) drug tremelimumab. The aim of this review was to systematically identify and revise the current scientific literature investigating the combination of these two drugs in solid tumors.

Methods

A digital search on the Medline (PubMed interface) and Scopus databases for articles published from inception to 26 February 2021 was performed. The terms used for the search were durvalumab AND tremelimumab. Trials reported in English involving adult patients with solid cancers tre

SUBMITTER: Arru C 

PROVIDER: S-EPMC8279985 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature